Skip to content
All news
Earnings

ServiceNow Targets $30B Subscription Revenue by 2030 on AI Growth

ServiceNow projects its subscription revenue will reach $30 billion by 2030, beating analyst estimates, fueled by its Now Assist AI platform which is expected to account for 30% of annual contract value.

May 7, 2026
2 min read
Source: GuruFocus.com
Share:

Key Numbers

2030 subscription revenue target
$30B
now assist acv share
30%

ServiceNow (NYSE: NOW) announced a target of $30 billion in subscription revenue by 2030, surpassing Wall Street estimates, driven by accelerating AI revenue from its Now Assist platform.

Key Financial Highlights

MetricValue
2030 subscription revenue target$30 billion
Now Assist share of annual contract value30%

Note: No specific quarterly results were released in this announcement.

Key Takeaways

ServiceNow stated that its generative AI platform, Now Assist, has become the primary growth driver, expected to represent 30% of new annual contract value. The company noted increasing demand for intelligent automation solutions across multiple sectors.

Future Guidance

ServiceNow aims to achieve $30 billion in annual subscription revenue by 2030, above the average analyst estimate of $25 billion. The forecast assumes continued customer adoption of AI products.

Stock Impact

ServiceNow shares (NOW) rose 5% in after-hours trading following the announcement of ambitious targets, reflecting investor optimism about the company's long-term growth prospects.

What This Means for Investors

ServiceNow's outlook signals a positive trajectory for its AI integration strategy, potentially boosting future revenue. However, investors should monitor execution risks amid rising competition in the enterprise software market.

Frequently Asked Questions

ServiceNow targets $30 billion in subscription revenue by 2030.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.